Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodine i 124 monoclonal antibody m5a is a radioimmunoconjugate composed of the humanized monoclonal antibody M5A labeled with the positron-emitting radionuclide iodine-124. The M5A antibody specifically targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), which is overexpressed on the surface of various cancer cells, particularly colorectal and other gastrointestinal cancers. By binding to CEA-positive tumor cells, this agent enables noninvasive imaging using PET scans to detect and localize tumors or metastases expressing CEA. The primary clinical application is in diagnostic imaging for staging and monitoring of CEA-expressing malignancies[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodine i 124 monoclonal antibody m5a.